Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Tesla gives encouraging update on 4680 battery cells
Tesla investors deliver rebuke as profit pressure intensifies
Trump boasts of his survival as Biden fights for his political life
Tesla accelerates plans for cheaper electric vehicles, but not the $25,000 EV
Police search for missing teenager last seen in reservoir